Nippon Shinyaku said on July 14 that it has filed three lawsuits against Sarepta Therapeutics in the US in a bid to defend the company’s intellectual property pertaining to technologies around its Duchenne muscular dystrophy (DMD) treatment Viltepso (viltolarsen). In…
To read the full story
Related Article
- Sarepta Drops DMD Drug Patent Claim against Nippon Shinyaku in Japan
January 31, 2025
- Nippon Shinyaku’s Viltepso Patents Invalid: US Jury Verdict
December 24, 2024
BUSINESS
- TS Alfresa-Backed Drone Council Inks Pact with Hiroshima
October 19, 2026
- Santen to Seek Bankruptcy for Chinese Subsidiary
October 19, 2026
- Toho Invests in Keio Offshoot AdipoSeeds
October 19, 2026
- Amgen, JASSO Team Up on Obesity Research and Care
October 19, 2026
- Sanwa Kagaku to Resume Kumamoto Production on October 19
October 19, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





